Before It Gets Better, It May Get Worse: What Your Doctor Knows About Prednisone That Most Patients Don't

When a physician writes a prescription for prednisone, the expectation — on both sides of the exam table — is usually relief. Prednisone is one of the most potent anti-inflammatory medications available, and for good reason: in many conditions, it delivers rapid, measurable improvement. But for a meaningful subset of patients, the first days or even weeks on this corticosteroid bring something unexpected. Symptoms intensify. The condition appears to flare. And patients, understandably alarmed, begin to wonder whether they are taking the right medication at all.

This is not a sign that the treatment is failing. In many cases, it is a sign that the treatment is working exactly as physiology dictates — just not on the timeline most patients anticipate.

The Immunological Setup

To understand why prednisone sometimes worsens symptoms before improving them, it helps to understand what it is actually doing inside the body. Prednisone is a prodrug, meaning the liver converts it into its active form, prednisolone, before it can exert its effects. Once active, it binds to glucocorticoid receptors throughout the body and begins suppressing immune activity — reducing the production of inflammatory cytokines, limiting white blood cell migration to inflamed tissue, and stabilizing cell membranes that would otherwise release pro-inflammatory compounds.

In theory, this process should deliver swift relief. In practice, however, the immune system does not simply stand down. Certain conditions — particularly those involving complex autoimmune dysregulation — involve overlapping inflammatory pathways that respond to corticosteroids at different rates. Some of those pathways, when partially suppressed, may temporarily shift the balance of immune activity in ways that cause symptoms to spike before a more complete suppression brings lasting calm.

Conditions Where This Pattern Is Most Common

Not every prednisone prescription carries the same risk of an initial worsening phase. The phenomenon is most commonly documented in a specific cluster of conditions.

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is among the most well-recognized contexts for this paradox. Patients initiating corticosteroid therapy for a moderate-to-severe flare occasionally report a brief period of increased cramping, urgency, or discomfort in the first few days of treatment. Clinicians attribute this partly to shifts in the intestinal immune environment and partly to the mechanical effects of inflammation resolving in stages rather than all at once.

Rheumatoid arthritis (RA) is another condition where early exacerbation can occur. The synovial joints affected by RA are sites of intense immune activity, and as prednisone begins redistributing immune cell populations, some patients experience a transient increase in joint stiffness or swelling before the sustained anti-inflammatory effect takes hold.

Lupus (systemic lupus erythematosus) presents a particularly nuanced picture. Because lupus involves immune complex deposition and complement activation — mechanisms that are not fully suppressed in the earliest phase of corticosteroid treatment — some patients experience a brief amplification of fatigue, joint pain, or skin manifestations before improvement begins.

Vasculitis and certain interstitial lung diseases also carry documented risks of early symptom fluctuation during corticosteroid initiation, particularly when the underlying inflammatory burden is high at the time treatment begins.

Why Physicians Prescribe It Anyway

The question that follows naturally is: if the drug can make things worse before making them better, why prescribe it at all?

The answer lies in risk calculus. For the conditions listed above, the alternative — allowing uncontrolled inflammation to persist — carries far greater long-term consequences than a temporary worsening phase. Unmanaged lupus nephritis can progress to kidney failure. Untreated severe IBD flares can lead to hospitalization, perforation, or surgical intervention. Active vasculitis can damage blood vessels supplying vital organs.

Against these risks, a brief period of heightened symptoms under medical supervision is, in most cases, an acceptable tradeoff. The physician prescribing prednisone in these scenarios is not being cavalier about the discomfort — they are making a considered judgment that the trajectory of the disease without treatment is far more dangerous than the temporary volatility that may accompany the drug's initiation.

The Dosing Variable

The likelihood and severity of an early worsening phase is also influenced by dosing strategy. In general, higher starting doses of prednisone — sometimes used in severe flares or acute inflammatory crises — tend to suppress immune activity more rapidly and may actually reduce the window of early symptom fluctuation. Lower starting doses, while associated with fewer immediate side effects, can sometimes allow a longer transitional period during which inflammation is only partially controlled.

This is one reason physicians do not simply default to the lowest effective dose when initiating treatment. The art of corticosteroid prescribing involves calibrating the starting dose to the severity of the condition, the patient's overall health profile, and the acceptable risk of an early exacerbation phase — a decision that looks different for every patient.

What Patients Should Watch For — and When to Call

Knowing that an early worsening phase is possible is not the same as accepting any degree of symptom escalation without medical input. There are important distinctions between expected transitional discomfort and a signal that something is genuinely wrong.

Patients should contact their prescribing physician if:

• Symptoms worsen dramatically rather than modestly in the first several days
• New symptoms emerge that were not present before starting prednisone
• Signs of infection appear, including fever, chills, or unusual discharge
• Symptoms show no sign of improvement after two weeks of consistent therapy
• Breathing difficulty, severe abdominal pain, or chest discomfort develops at any point

In contrast, mild-to-moderate fluctuation in the first three to seven days — particularly in conditions like IBD or RA — may fall within the expected pattern and does not necessarily warrant discontinuing the medication.

The Risk of Stopping Too Soon

One of the most clinically significant consequences of the early worsening phenomenon is premature discontinuation. Patients who are not prepared for the possibility of initial symptom amplification sometimes interpret it as a sign that the medication is contraindicated for them, and stop taking it without medical guidance.

Abruptly stopping prednisone carries its own serious risks. Because the drug suppresses the adrenal glands' natural cortisol production, sudden discontinuation can precipitate adrenal insufficiency — a condition marked by severe fatigue, low blood pressure, nausea, and in serious cases, a life-threatening adrenal crisis. Beyond that physiological risk, stopping prednisone before it has had time to work often allows the underlying inflammatory condition to rebound, sometimes with greater intensity than before.

This is why communication with your care team is essential throughout the initiation phase of prednisone therapy. If symptoms are worsening, that is a conversation to have with your physician — not a decision to act on unilaterally.

Setting Realistic Expectations Before Day One

The most effective thing a patient can do before starting prednisone is ask their physician directly: Is there any chance my symptoms could get worse before they improve on this medication? For many conditions, the honest answer is yes — and knowing that in advance changes everything about how a patient experiences the first week of treatment.

At PrednisoneMD, our goal is to ensure that patients have the clinical context they need to make informed decisions and stay the course when staying the course is the right call. Prednisone is a powerful, evidence-backed medication. But its power is only realized when patients understand the full arc of how it works — including the part that comes before the relief.